Annovis Bio (NYSE: ANVS) has announced it will begin an open-label extension (OLE) study in January 2026 to evaluate the long-term safety and efficacy of buntanetap in Parkinson’s disease (PD) patients.
The study aims to enroll 500 patients who will be treated with buntanetap for 36 months.
In a statement, Maria Maccecchini, PhD, president and CEO of Annovis, commented, “Launching the OLE study is a natural next step for our Parkinson’s program. In our previous PD trial, many patients shared they experienced noticeable improvements and were eager to stay on treatment. Being able to offer them continued access to buntanetap truly matters to us.”
Dr. Maccecchini added, “At the same time, this study will allow us to take a longer-term view of buntanetap. By following patients over an extended period, we will further measure buntanetap’s safety and evaluate its sustained benefits on both motor and cognitive functions. Collecting biomarker data will also help us deepen our understanding of buntanetap’s potential as a disease-modifying treatment.”
